VAM
IPXL

Visium Asset Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Visium Asset Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-9,900
Closed -$249K – 1097
2013
Q4 		$249K Buy
+9,900
New +$221K ﹤0.01% 746

Other funds holding IPXL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Visium Asset Management's IPXL Position: Q1 2014 in Review

Visium Asset Management sold out of Impax Laboratories, Inc. (IPXL) in Q1 2014, closing a stake of 9,900 shares — an estimated $249K sold.

Visium Asset Management first reported a position in IPXL in Q4 2013 and held it in 1 quarter. The position peaked at $249K in Q4 2013. 181 funds tracked by Wall St. Rank hold IPXL as of Q1 2014.

  • Visium Asset Management reported no remaining Impax Laboratories, Inc. position as of Q1 2014 after selling out during the quarter.
  • Visium Asset Management sold 9,900 Impax Laboratories, Inc. shares in Q1 2014, an estimated $249K.
  • Visium Asset Management first reported a position in Impax Laboratories, Inc. in Q4 2013 and held it in 1 quarter.
  • Visium Asset Management's Impax Laboratories, Inc. position peaked at $249K in Q4 2013.
  • 181 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2014.

Based on Visium Asset Management's 13F filing for Q1 2014, filed 15 May 2014.